Tan Li, Li Qing-Shu, Peng Dong, Cheng Yong
Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Department of Pathology, School of Basic Medicine, Chongqing Medical University, Chongqing, China.
Front Oncol. 2023 Jan 13;12:976622. doi: 10.3389/fonc.2022.976622. eCollection 2022.
Colorectal cancer (CRC) ranks third in highest incidence among human cancers. With the continuous development of anti-cancer drugs, CRC patients are treated more and more effectively. However, the treatment of patients with unresectable metastatic CRC (mCRC) remains a core point for surgeons worldwide, especially for those with microsatellite stability (MSS) and BRAF V600E mutation, who have been reported to have the worst prognosis.
We report a case of pathological complete remission in a patient with unresectable MSS, BRAF V600E-mutated metastatic rectal cancer after using Vemurafenib and Cetuximab in combination with Camrelizumab.
This case suggested that Vemurafenib and Cetuximab combined with Camrelizumab is effective in the treatment of MSS, BRAF V600E-mutated mCRC. To benefit more patients, further studies need to be completed.
结直肠癌（CRC）在人类癌症发病率中排名第三。随着抗癌药物的不断发展，CRC患者的治疗越来越有效。然而，不可切除转移性CRC（mCRC）患者的治疗仍然是全球外科医生关注的核心问题，尤其是对于微卫星稳定（MSS）和BRAF V600E突变的患者，据报道这些患者预后最差。
我们报告了1例不可切除的MSS、BRAF V600E突变转移性直肠癌患者在使用维莫非尼、西妥昔单抗联合卡瑞利珠单抗后达到病理完全缓解的病例。
该病例表明，维莫非尼、西妥昔单抗联合卡瑞利珠单抗治疗MSS、BRAF V600E突变的mCRC有效。为使更多患者受益，需要完成进一步研究。
